| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4419 | Rhlr Antagonist E22 | Quorum sensing modulator as a RhlR antagonist |
|
| DCC4420 | rhm-138 | Selective sigma-2 ligand, inducing apoptosis in EMT-6 breast cancer cells |
|
| DCC4421 | Rhodblock 1a | Potent inhibitor of the Rho pathway |
|
| DCC4422 | Ricasetron | Selective antagonist of the serotonin 5-HT3 receptor |
|
| DCC4423 | Rifametane | Antibiotic for tuberculosis (TB) treatment |
|
| DCC4424 | Rifamycin Sv | Natural antibiotic, inhibiting prokaryotic DNA-dependent RNA synthesis and protein synthesis; blocking RNA-polymerase transcription initiation, modulating ß2m aggregation |
|
| DCC4425 | Rilmazafone | Water-soluble benzodiazepine prodrug, as a sedative and hypnotic neuropsychiatric agent |
|
| DCC4426 | Rilpivirine Hydrochloride | HIV-1 reverse transcriptase inhibitor, also acting as an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor |
|
| DCC4427 | R-imeglimin | Novel antidiabetic agent, impairing glucose uptake by muscle tissue, excessing hepatic gluconeogenesis, and increasing beta-cell apoptosis |
|
| DCC4428 | Rinoxiab | Natural inducer of apoptosis by significantly upregulating Bcl-2, mitigating expression of Bcl2 in HCT 15 cells and attenuating the apoptotic markers and cell cycle regulatory proteins |
|
| DCC4429 | Rip2-in-3 | First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific inhibitor |
|
| DCC4430 | Ripk2 Protac 20 | Novel IAP-based selective RIPK2 degrader |
|
| DCC4431 | Rivoglitazone Hydrochloride | Novel peroxisome proliferator-activated receptor gamma (PPARgamma) agonist |
|
| DCC4432 | Rjr-2403 Fumarate | Highly selective α4β2 subtype nicotinic receptor agonist |
|
| DCC4433 | Rjw100 | Novel potent Liver Receptor Homolog-1 (LRH-1) modulator |
|
| DCC4434 | Rk-0404678 | Novel inhibitor of dengue virus NS5 RNA-dependent RNA polymerase (RdRp), inhibiting the DENV type 2 (DENV2) RdRp activities |
|
| DCC4435 | Rk-682 | Natural selective inhibitor of protein tyrosine phosphatases (PTPases) |
|
| DCC4436 | Rk-9123016 | Novel potent and selective SIRT2 inhibitor, increasing the acetylation level of eukaryotic translation initiation factor 5A (eIF5A) and reducing cell viability of human breast cancer cells accompanied with a decrease in c-Myc expression |
|
| DCC4437 | Rkn5755 | Novel selective inhibitor of activated fibroblasts, inhibiting the enhanced migration of fibroblasts cocultured with cancer cells by binding to β-arrestin1 and interfering with β-arrestin1-mediated cofilin signaling pathways |
|
| DCC4438 | Rl-338 | Novel potent and highly selective GPR6 inverse agonist, inhibiting GPR6 cAMP signalling in TR-FRET assays with a EC50 = 16 nM and >100 fold selectivity against GPR3 and GPR12 |
|
| DCC4439 | Rm-131 | Novel gastrocolokinetic ghrelin agonist, approximately sixfold greater potency than natural ghrelin |
|
| DCC4440 | Rm-133 | Promising pro-apoptotic agent, showing activity on various cancer cell lines |
|
| DCC4441 | Rm1490 | Novel MOR agonist |
|
| DCC4442 | Rm-581-fluo | Novel Fluorescent ER-Tracker dye, showing potent cytotoxic activity on several types of cancer cells, being accumulated into the endoplasmic reticulum (ER) as highlighted by its colocalization |
|
| DCC4443 | Rms-07 | The first irreversible covalent MPS1 inhibitor, targeting a poorly conserved cysteine in the kinase's hinge region |
|
| DCC4444 | rn-450 | Potent, reversible, non-carbonyl inhibitor of fatty acid amide hydrolase (FAAH) |
|
| DCC4445 | Rna Ligand Tppc | Novel potent and specific RNA-binding ligand, targeting riboswitches and other RNAs at proximal subsites |
|
| DCC4446 | Ro 04-5595 Hydrochloride | Selective antagonist of NMDA receptors NR2B subunits |
|
| DCC4447 | ro 115-1240 | Selective alpha1A/1L-adrenoceptor partial agonist |
|
| DCC4448 | Ro 25-6981 Benzoate | Potent and selective antagonist of NMDA glutamate receptors containing the NR2B subunit |
|
